Clinical Trial Search

Phase 3 N=302 Once-Daily Investigational Nasal Spray In Adults And Adolescents With Perennial Allergic Rhinitis (PAR)

Rhinitis, Allergic, Perennial

Primary: Mean Change From Baseline (Day 1) Over the Entire Treatment Period in Daily, Reflective Total Nasal Symptom Scores (rTNSS) Over 6 Weeks — -2.69; -3.95 Scores on a scale…

GlaxoSmithKline Results Apr 2018 0.3% serious AE View details

Phase 3 N=609 Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea

Clostridium Difficile Infection

Primary: Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population — 81; 85.7 Percentage of participants

Actelion Results Apr 2018 13.5% serious AE View details

Phase 3 N=265 A Study of the Efficacy and Safety of DFD-06 Cream in the Treatment of Moderate to Severe Plaque Psoriasis

Chronic Stable Plaque Psoriasis

Primary: Efficacy (Percentage of Subjects With Treatment Success) — 30.1; 9.7 percentage of participants

Promius Pharma, LLC Results Apr 2018 0.4% serious AE View details

Phase 3 N=270 A Study to Demonstrate the Efficacy and Tolerability of Ferrous Bisglycinate Chelate in Iron Deficiency Anaemia and to Compare These With Those of Ferrous Ascorbate.

Haematopoiesis

Primary: Change From Baseline in Hemoglobin (Hb) After 8 Weeks of Treatment in Each Ferrous Bisglycinate Chelate Group (1 Tablet Daily and 2 Tablets Daily) — 2.6; 2.8 Gram per…

GlaxoSmithKline Results Apr 2018 0.0% serious AE View details

Phase 3 N=133 A Study of Subcutaneous (SC) Tocilizumab (RoActemra/Actemra) in Participants With Active Rheumatoid Arthritis (RA) and Inadequate Response to Disease-Modifying Anti-Rheumatic Drugs (DMARDs)

Rheumatoid Arthritis

Primary: Change From Baseline in Clinical Disease Activity Index (CDAI) at Week 12 — 24.9; -16.6 units on a scale

Hoffmann-La Roche Results Apr 2018 9.0% serious AE View details

Phase 3 N=5,285 A Study to Evaluate the Safety and Efficacy of Inactivated Varicella-zoster Vaccine (VZV) as a Preventative Treatment for Herpes Zoster (HZ) and HZ-related Complications in Adult Participants With Solid Tumor or Hematologic Malignancy (V212-011)

Herpes Zoster

Primary: Incidence of Confirmed Herpes-Zoster — 6.737; 18.457 Number of cases per 1000 person years

Merck Sharp & Dohme LLC Results Apr 2018 50.0% serious AE View details

Phase 3 N=1,538 A Study in Patients With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2

Primary: Change From Baseline to 52 Week Endpoint in Hemoglobin A1c (HbA1c) — -1.55; -1.25 percentage of HbA1c

Eli Lilly and Company Results Apr 2018 11.6% serious AE View details

Phase 3 N=267 A Study of the Efficacy and Safety of DFD-06 Cream in the Treatment of Moderate to Severe Plaque Psoriasis

Psoriasis

Primary: Percentage of Subjects With Treatment Success at Day 15 — 30.2; 9.0 percentage of participants

Promius Pharma, LLC Results Apr 2018 0.4% serious AE View details

Phase 3 N=150 Efficacy and Safety of Pasireotide Administered Monthly in Patients With Cushing's Disease

Cushing's Disease

Primary: Percentage Participants That Attained a mUFC ≤ 1.0 x ULN at Month 7 Regardless of Dose Titration — 41.9; 40.8 percentage of participants

Novartis Pharmaceuticals Results Apr 2018 27.3% serious AE View details

Phase 3 N=298 Addressing Involuntary Movements in Tardive Dyskinesia

Tardive Dyskinesia

Primary: Change in Total Motor Abnormal Involuntary Movement Scale (AIMS) Score From Baseline to Week 12 Using a Mixed Model For Repeated Measures (MMRM) — -1.4; -2.1; -3.2; -3.3…

Auspex Pharmaceuticals, Inc. Results Apr 2018 5.5% serious AE View details

Phase 3 N=931 A Study of Atezolizumab Compared With Chemotherapy in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer [IMvigor211]

Bladder Cancer

Primary: Overall Survival (OS) — 10.6; 11.1; 8.2; 8.9 Months — p=0.4134

Hoffmann-La Roche Results Apr 2018 42.2% serious AE View details

Phase 3 N=220 Demonstrate Noninferiority in Efficacy and to Assess Safety of CT-P13 in Patients With Active Crohn's Disease

Crohn's Disease

Primary: The Number and Percentage of Patients Achieving Clinical Response According to Crohn's Disease Activity Index (CDAI)-70 Criteria at Week 6 — 77; 81 Participants

Celltrion Results Apr 2018 8.6% serious AE View details

Phase 3 N=10 Study of Long-term Safety, Efficacy Tolerability of BYM338 in Patients With Sporadic Inclusion Body Myositis

Sporadic Inclusion Body Myositis (sIBM)

Primary: Number of Participants With Adverse Events as a Measure of Safety and Tolerability — 0; 2; 10 Participants

Novartis Pharmaceuticals Results Apr 2018 20.0% serious AE View details

Phase 3 N=264 Study to Evaluate Safety and Efficacy of Rifamycin SV Multi-Matrix System (MMX) for the Treatment of Traveler's Diarrhea (TD)

Traveler's Diarrhea

Primary: Time to Last Unformed Stool (TLUS) — 37.4; 21.; 68; 46 TLUS (hours)

Cosmo Technologies Ltd Results Apr 2018 1.1% serious AE View details

Phase 3 N=100 Study Assessing The Interest of Indocyanine Green Fluorescence Imaging With Radioisotope Method For Sentinel Lymph Node Biopsy in Patients With Breast Cancer

Breast Neoplasms

Primary: Number of Patients With Less Than Two Lymph Nodes Detected — 22; 20 Participants

Centre Hospitalier Universitaire de Saint Etienne Results Apr 2018 0.0% serious AE View details